Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session and finished the day at $3.84. Traded volume was 9.38million shares in the last session and the average volume of the stock remained 2.56million shares. The beta of the stock remained 2.08. Zogenix, Inc. (NASDAQ:ZGNX) insider ownership is 0.10%.

Boston Scientific Corp. (NYSE:BSX)’s SVP David A. Pierce sold 5,316 shares of Boston Scientific Corp. stock in a transaction that occurred on Thursday, March 6th. Boston Scientific Corporation (NYSE:BSX) rose 1.27 percent to $13.55 yesterday on volume of BSX 9.38million shares. The intra-day range of the stock was $13.43 to $13.59. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $17.94billion.

Beleaguered biotech firm Galena Biopharma Inc (NASDAQ:GALE) is facing another lawsuit over insider stock sales filed by purchasers of the company’s stock. Galena Biopharma Inc (NASDAQ:GALE)’s stock on Mar 06, 2014 reported a decrease of -10.82% to the closing price of $3.46. Its fifty two weeks range is $1.65 -$7.77. The total market capitalization recorded $364.12billion. The overall volume in the last trading session was 10.17million shares. In its share capital, Galena Biopharma Inc (NASDAQ:GALE) has 87.32million outstanding shares.

A new, highly effective drug for treating hepatitis C—hailed as a cure for the disease—costs up to $84,000 per person, and is raising questions about the affordability of life-saving medications. In the past, the only way to cure hepatitis C has been with a liver transplant, so the new drugs, including Gilead Science Inc. (NASDAQ:GILD)’s Sovaldi, are good news for patients. On Wednesday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped -3.56% to close the day at $79.92. Company return on investment (ROI) is 28.60% and its monthly performance is recorded as -2.56%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is 10.36%.